Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women

American Journal of Clinical Nutrition

Volumn 67, Issue 4, 1998, Pages 611-615

  Flechtner Mors, Marion ^a   Ditschuneit, Herwig H ^b   Yip, Ian ^b   Adler, Guido ^b  

^a UNIVERSITY OF ULM   (Germany)

^b NONE

Author keywords

Blood pressure; Body weight; Dexfenfluramine; Epinephrine; Hypertension; Insulin; Obesity; Postmenopausal women

Indexed keywords

ADRENALIN; DEXFENFLURAMINE; GLUCOSE; INSULIN; NORADRENALIN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; NORADRENALIN BLOOD LEVEL; OBESITY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

EID: 0031965744     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/67.4.611     Document Type: Article

References (31)

1. Guy-Grand B, Crepaldi G, Lefebvre P, Gries A. International trial of long-term dexfenfluramine in obesity. Lancet 1989;2:1142-4.
2. Turner P. Dexfenfluramine. Its place in weight control. Drugs 1990;39(suppl 3):53-62.
3. McTavish D, Heel RC. Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity. Drugs 1992;43:713-33.
4. Blundell JE. Serotonin and the biology of feeding. Am J Clin Nutr 1992;55:1555-95.
5. Mathus-Vliegen EMH. Prolonged surveillance of dexfenfluramine in severe obesity. Neth J Med 1993;43:246-53.
6. Enzi G, Crepaldi G, Inelmen EM, Bruni R, Baggio B. Efficacy and safety of dexfenfluramine in obese patients: a multicenter study. Clin Neuropharmacol 1988;11:S173-8.
7. Noble RE. A six-month study of the effects of dexfenfluramine on partially successful dieters. Curr Ther Res 1990;47:612-9.
8. Breed J, Bronsveld W, Spijker A, et al. Effects of dexfenfluramine on body weight, blood pressure and glucose metabolism in obese hypertensive patients. Int J Obes 1994;18:105 (abstr).
9. Kolanowski J, Younis LT, Vanbutsele R, Detry JM. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. Eur J Clin Pharmacol 1992;42:599-606.
10. Berlin I, Puech AJ. Is it dexfenfluramine or weight loss that reduces blood pressure and noradrenergic activity in obese patients? Eur J Clin Pharmacol 1993;44:601 (letter).
11. Andersson B, Zimmermann ME, Hedner T, Björntorp P. Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women. Eur J Clin Pharmacol 1991;40:249-54.
12. Ditschuneit HH, Flechtner-Mors M, Dolderer M, Fulda U, Ditschuneit H. Endocrine and metabolic effects of dexfenfluramine in patients with android obesity. Horm Metab Res 1993;25:573-8.
13. Holdaway IM, Wallace E, Westbrooke L, Gamble G. Effect of dF on body weight, blood pressure, insulin resistance and serum cholesterol in obese individuals. Int J Obes 1995;19:749-51.
14. O'Brien E. Blood pressure measurement. In: Swales JD, ed. Textbook of hypertension. Oxford, United Kingdom: Blackwell Scientific Publications, 1994:989-1008.
15. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
16. Owen OE, Kavle E, Owen RS, et al. A reappraisal of caloric requirements in healthy women. Am J Clin Nutr 1986;44:1-19.
17. O'Connor HT, Richman RM, Steinbeck KS, Caterson ID. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. Int J Obes 1995;19:181-9.
18. Pfohl M, Luft D, Blomberg I, Schmülling R-M. Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine. Int J Obes 1994;18:391-5.
19. Mancia G, Ferrari A, Gregorini L, Leonetti G. Plasma catecholamines do not invariably reflect sympathetic induced changes in blood pressure in man. Clin Sci 1983;65:227-35.
20. Young JB, Landsberg L. Suppression of sympathetic nervous system during fasting. Science 1977;196:1473-5.
21. Jung RT, Shetty PS, Barrand M, Callingham BA, James WPT. Role of catecholamines in hypotensive response to dieting. Br Med J 1979;1:12-23.
22. Schutz Y, Bessard T, Jéquier E. Diet-induced thermogenesis measured over a whole day in obese and nonobese women. Am J Clin Nutr 1984;40:542-52.
23. Troisi RJ, Weiss ST, Parker DR, Sparrow D, Young JB, Landsberg L. Relation of obesity and diet to sympathetic nervous system activity. Hypertension 1991;17:669-77.
24. Schwartz RS, Halter JB, Bierman EL. Reduced thermic effect of feeding in obesity: role of norepinephrine. Metabolism 1983; 32:114-7.
25. Sowers JR, Whitfield LA, Catania RA. Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab 1982;54:1181-6.
26. Maxwell MH, Heber D, Waks AU, Tuck ML. Role of insulin and norepinephrine in the hypertension of obesity. Am J Hypertens 1994;7:402-8.
27. Kush RD, Young JB, Katzeff HL. Effect of diet on energy expenditure and plasma norepinephrine in lean and obese Pima Indians. Metabolism 1986;35:1110-20.
28. Kjeldsen SE, Eide I, Aakesson I, Leren P. Influence of body weight on plasma catecholamine patterns in middle-aged, normotensive men. Scand J Clin Lab Invest 1983; 43:339-42.
29. Peterson HR, Rothschild M, Weinberg CR, Fell RD, McLeish KR, Pfeifer MA. Body fat and the activity of the autonomic nervous system. N Engl J Med 1988;318:1077-83.
30. Katzeff HL, O'Connell M, Horton ES, Danforth E, Young JB, Landsberg L. Metabolic studies in human obesity during overnutrition and undernutrition: thermogenic and hormonal responses to norepinephrine. Metabolism 1986;35:166-75.
31. Bray GA. Autonomic and endocrine factors in the regulation of energy balance. Fed Proc 1986;45:404-10.